1. Home
  2. BMEA

BMEA

Biomea Fusion Inc.

Logo Biomea Fusion Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 1:54pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Founded: 2017 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 465.8M IPO Year: 2021
Target Price: $47.09 AVG Volume (30 days): 1.0M
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.44 EPS Growth: N/A
52 Week Low/High: $8.13 - $43.69 Next Earning Date: 04-30-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: